Type I Collagen Is a Molecular Target for Inhibition of Angiogenesis by Endogenous Thrombospondin-1
Total Page:16
File Type:pdf, Size:1020Kb
Oncogene (2006) 25, 536–545 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ORIGINAL ARTICLE Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1 L Zhou1, JS Isenberg1, Z Cao and DD Roberts Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Three-dimensional explant cultures of muscle tissue were stat-Saslow et al., 1994; Tenan et al., 2000; Streit et al., used to characterize secreted proteins regulated by 2002).TSP1 gene expression is lost during progression endogenous levels of the angiogenesis modulator thrombo- of a number of cancer types, but TSP1 levels in some spondin (TSP)-1. Explants from TSP1 null mice exhibit tumor types remain high due to induced expression of enhanced neovascularization associated with increased TSP1 by stromal cells (reviewed in Lawler and Detmar, endothelial outgrowth but decreased outgrowth of peri- (2004)).Studies using transgenic mice confirmed that vascular smooth muscle cells . The absence of endogenous host endogenous TSP1 plays an important role in TSP1 did not diminish activation of latent transforming limiting neovascularization of tumors (Lawler et al., growth factor-b and moderately decreased matrixmetal- 2001; Hamano et al., 2004). loproteinase levels. However, significant changes in other Antiangiogenic fragments and peptides derived from secreted proteins were observed. Endogenous TSP1 TSP1 can inhibit angiogenesis and tumor growth in decreased mRNA levels for collagens Ia1, Ia2, and IIIa1 animals (Tolsma et al., 1993; Guo et al., 1997b; and laminin a4 and increased collagen IVa1 mRNA Bogdanov Jr et al., 1999; Iruela-Arispe et al., 1999; expression. Endogenous TSP1 also decreased the level of Westphal, 2004; Yee et al., 2004). However, adverse type I collagen protein produced by the vascular out- tumor responses to other TSP1 constructs have been growths. Collagens Ia1, Ia2, and IIIa1 are known tumor observed (de Fraipont et al., 2004), and some TSP1 endothelial markers, suggesting that TSP1 coordinately fragments have clear proangiogenic activities (Chandra- regulates a set of extracellular matrix genes that reverse sekaran et al., 2000; Calzada et al., 2004). Furthermore, the angiogenic switch. Suppression of collagen Ia1orIa2 some tumors become resistant to TSP1 (Filleur et al., mRNAs using antisense morpholinos inhibited outgrowth 2001), so successful use of TSP1-derived drugs will in TSP1 null explants and proliferation of TSP1 null require a deeper understanding of the mechanisms by endothelial cells, indicating that type I collagen synthesis which TSP1 regulates angiogenesis. is limiting for this neovascularization response. At least eight TSP1 receptors mediate its effects on Oncogene (2006) 25, 536–545. doi:10.1038/sj.onc.1209069; endothelial cells, and of these CD36 (Jimenez et al., published online 10 October 2005 2000; Jimenez et al., 2001), heparan sulfate proteogly- cans (Guo et al., 1997a; Iruela-Arispe et al., 1999), Keywords: 3D culture; endothelial cells; angiogenesis CD47 (Kanda et al., 1999), and a3b1 (Chandrasekaran inhibitors; collagens et al., 2000) and a4b1 integrins modulate angiogenesis (Calzada et al., 2004). TSP1 induces expression of matrix metalloproteinase (MMP)-2 and MMP-9 in endothelial cells (Qian et al., 1997; Taraboletti et al., Introduction 2000), but direct interactions of TSP1 with MMPs may counteract this by inhibiting MMP activities or Thrombospondins (TSPs) are a family of five secreted mediating their degradation (Bein and Simons, 2000; proteins that are transiently or constitutively expressed Rodriguez-Manzaneque et al., 2001). Activation of in the extracellular matrices of various tissues (Born- latent TGFb also mediates some effects of TSP1 on stein, 2001; Adams and Lawler, 2004).Two members of endothelial cell proliferation (reviewed in Murphy- this family, TSP1 and TSP2, are potent inhibitors of Ullrich and Poczatek, (2000)) and tumor growth (Yee angiogenesis and have antitumor activities in several et al., 2004). Signaling through the CD36 receptor tumor xenograft models (Dameron et al., 1994; Wein- results in phosphorylation of c-Jun N-terminal kinase, which is required for inhibition of angiogenesis in vivo Correspondence: Dr DD Roberts, Biochemical Pathology Section, (Jimenez et al., 2001). A cascade involving phosphoryla- National Cancer Institute, National Institutes of Health, Building 10 tion of p59fyn, caspase-3 like proteases, and p38 Room 2A33, 10 Center Dr MSC 1500, Bethesda, MD 20892-1500, mitogen-activated protein kinases is also stimulated by USA. TSP1 through CD36 and mediates induction of Fas- E-mail: [email protected] 1These two authors contributed equally to this work. dependent endothelial cell apoptosis (Jimenez et al., Received 24 March 2005; revised 1 July 2005; accepted 1 August 2005; 2000; Volpert et al., 2002). TSP1 also regulates published online 10 October 2005 cytoskeletal actin in endothelial cells and inhibits Thrombospondin-1 targets in angiogenesis L Zhou et al 537 formation of lamellipodia associated with increased response to serum and growth factors in the lower phosphorylation of hsp27 and cofilin (Keezer et al., chamber was counted (Figure 1a).More vascular cells 2003). from the TSP1 null explants migrated through the In addition to endothelial cells, angiogenesis involves membrane than did those from WT explants.Therefore, pericytes, fibroblasts, immune cells, and mast cells. expression of endogenous TSP1 in the WT explants These cells express cytokines and growth factors that inhibits migration of vascular outgrowth cells. regulate endothelial cell proliferation, migration, inva- Invasive activity of outgrowth cells from muscle sion, tube formation, and vessel stabilization (Eliceiri explants was evaluated using 8 mm inserts precoated and Cheresh, 2001).Many of these cell types also with a barrier of polymerized type I collagen respond directly to TSP1 in vitro (Majack et al., 1986; (Figure 1b).The inserts were placed into wells contain- Sunderkotter et al., 1994; Chen et al., 1999; Isenberg ing MDA-MB-435 breast cancer cells to supply angio- et al., 2005). Therefore, interactions of TSP1 with genic factors, and the muscle explants were placed into several receptors and with several cell types probably the upper compartments.After 6 days, more cells from contribute to its modulation of angiogenesis.Specific the TSP1 null mice muscle explants invaded through the TSP1 receptors may also be differentially expressed or collagen barrier than did those cells from WT explants. utilized in specific types of developmental and patho- MDA-MB-435 cells do not express significant TSP1 logical angiogenesis. (Zabrenetzky et al., 1994). Therefore, endogenous TSP1 Given this complexity in cellular responses to TSP1, produced by the explants also suppresses the invasive we must first establish experimental systems wherein the functions of multiple receptors and vascular cell types in responding to TSPs can be quantified simultaneously to understand how TSP1 influences tumor angiogenesis. We recently established an ex vivo model for this purpose that can be used to identify the cellular and molecular targets of endogenous TSP1 in angiogenic responses (Calzada et al., 2004; Isenberg et al., 2005). Muscle explants from TSP1 null mice grown in three- dimensional (3D) cultures showed the predicted increase in endothelial outgrowth, whereas vascular smooth muscle cell outgrowth was deficient in the absence of endogenous TSP1 (Isenberg et al., 2005). Using the same explant model, we defined a role for its receptor a4b1 integrin in mediating effects of endogenous TSP1 on vascular outgrowth and showed that an antagonist of a4b1 selectively inhibited outgrowth of wild-type (WT) explants (Calzada et al., 2004). We have now used the 3D explant assay to identify secreted molecular targets of TSP1 in neovascularization and to test the function of secreted proteins that are known targets of TSP1.By this approach, we found type I collagen expression to be dependent on endogenous TSP1.Levels of mRNA for several other collagen genes and laminin a4 differed between vascular outgrowths from null and WT explants.Using antisense morpholinos, we found that collagen Ia1orIa2 are limiting for angiogenic responses of TSP1 null explants in a 3D matrix.As these changes mirror those recently identified for the same collagen Figure 1 Endogenous TSP1 inhibits random migration and genes in human tumor endothelium (St Croix et al., directed invasion of outgrowth cells from murine muscle explants. 2000; Madden et al., 2004) and metastatic tumors (a) Outgrowth cell migration was examined by culturing muscle explants to the upper compartments of 8 mm polycarbonate (Ramaswamy et al., 2003), the muscle explant assay membrane tissue culture inserts in EBM medium.After 6 days, may facilitate study of the angiogenic switch in cancer. cells that migrated to the underside of the filters were counted in five randomly chosen microscope fields.( b) The invasion of vascular cells from muscle was evaluated.Polycarbonate inserts (8 mm) were precoated with 50 mg collagen I and placed in the upper compartments of 24-well plate to which 5000 MDA-MB-435 Results human breast cancer cells/well were plated in RPMI 1640 medium containing 10% FBS to supply angiogenic factors.Muscle explants Endogenous TSP1 inhibits invasion of outgrowth cells were placed into the upper compartments and cultured in EBM To better quantify migratory activity